The definition of residual neuromuscular blockade is a train-of-four ratio (TOF) of <0.9 using mechanomyography. This is based on the demonstration of upper airway obstruction, pharyngeal dysfunction and pulmonary aspiration in partially paralysed volunteers 1, 2 . The clinical significance of this was emphasised in 2002 when the Anaesthetic Incident Monitoring Survey study showed residual neuromuscular block to be the major contributor to critical respiratory events in the postoperative recovery period 3 . In 2010-2011 the incidence of residual blockade was still as high as 31-64%, leading many eminent authors to call for new guidelines for the safe use of neuromuscular blocking agents [4] [5] [6] [7] [8] [9] [10] . Overseas surveys have shown disparate opinions regarding the need for neuromuscular function monitoring and limited penetration of awareness of the latest research, with less than 50% of anaesthetists routinely using neuromuscular function monitors [11] [12] [13] .
The Australian and New Zealand College of Anaesthetists guidelines in relation to Neuromuscular Transmission Monitoring (Professional Standard 18, 3.10, 2008) recommend that a neuromuscular function monitor be available for every patient in whom neuromuscular blockade is used. However, it is not known how often they are actually used. In 2011, we conducted a cross-sectional online survey to investigate the attitudes, knowledge and practices of Australian and New Zealand anaesthetists in relation to their use of neuromuscular function monitors.
MATERIALS AND METHODS
This survey had the approval of the Human Ethics and Research Committee of the Sydney Adventist Hospital (EC00141: project 2011/017). We invited all medical practitioner members of the Australian Society of Anaesthetists and the New Zealand Society of Anaesthetists who had an email address registered with those institutions to complete the 
SUMMARy
This survey of anaesthetists in Australia and New Zealand aimed to investigate their attitudes and practice relating to the management of neuromuscular blockade monitoring. All medical practitioner members (3188) of the Australian and New Zealand Societies of Anaesthetists were invited to complete an anonymous survey, which was available online for two months. A total of 678 survey questionnaires were completed (response rate 21%). Most respondents (71.4%) underestimated the incidence of residual neuromuscular blockade and 63.2% believed this to be a significant clinical problem. Objective monitoring of neuromuscular function was used routinely only by 17% of respondents, although 70% believed routine monitoring would reduce the incidence of residual neuromuscular blockade. Only 25% of respondents correctly indicated that quantitative train-of-four counts of greater than 90% were the accepted criteria for safe extubation, with 52% using clinical judgement only. Only 29% of respondents believed neuromuscular function monitors should be part of minimum monitoring standards; quantitative neuromuscular function monitors were not available in 42% of the hospitals in which the respondents practiced. Despite the low response rate, the large sample size and heterogeneity of respondents make the findings of this survey concerning. There is a need for more education, availability of appropriate monitoring equipment and evidence-based guidelines for management of neuromuscular blockade in Australia and New Zealand. online survey. This allowed doctors practising anaesthesia who are not Fellows of the Australian and New Zealand College of Anaesthetists to participate. The survey was available online for two months, and potential respondents were reminded to respond in the monthly e-newsletter of both Societies with an invitation to the link. The survey was constructed and distributed using a commercial online survey vehicle (Survey Monkey), which was Internet Protocol address sensitive and only allowed one response per email address. Respondents completed the surveys anonymously and no record of the email address was linked to the response. The survey was encrypted with a secure sockets layer to ensure privacy and message authentication.
The survey was developed by the investigators and based initially on that used by Naguib et al, with permission 11 . Questions to determine observations and attitudes to residual neuromuscular blockade, availability and use of neuromuscular transmission monitors, neuromuscular blocking antagonists and safe tracheal extubation criteria were developed. The survey was deliberately brief to try to maximise response rate. A small, local hard-copy pilot study identified a few minor issues which were rectified before the online survey was launched. An opportunity to provide free text was provided at the end of the survey.
On the basis of previously published email surveys of anaesthetists, we expected a response rate between 10-35% (631 responses) 11, 14 . As relatively small response rates are subject to sampling bias, questions to characterise the demographics of respondents were included: practice location, size of hospital and years of experience. Residual neuromuscular blockade was defined as a TOF <0.9 using any form of quantitative monitor. Quantitative monitors give an objective numerical response to the selected stimulus. (Examples of such monitors commercially available in Australasia are electromyography, acceleromyography and kinemyography). Qualitative neuromuscular function monitors were defined as those that required a subjective interpretation of the patient response, such as a peripheral nerve stimulator. (Tactile or visual assessment of fade cannot be detected with these monitors once the TOF recovers past 0.4) [15] [16] [17] .
RESULTS
In Australia, 2745 email invitations were sent to anaesthetists in July 2011, which included 537 retired anaesthetists. A total of 170 (6.19%) emails bounced back, implying an incorrect email address.
A total of 549 (20%) were not opened. A total of 1303 emails were opened. The outcome of the other emails is not known. A total of 568 anaesthetists entered the survey. One respondent did not complete the survey questionnaire, stating his retirement The respondents were heterogeneous. Seventysix percent described their main practice location as urban, and 66% as public hospital based. The practice characteristics of respondents are shown in Tables 1-3 .
The frequency of residual neuromuscular blockade estimated by the respondents is shown in Table 4 . (Note that 26% of respondents chose not to estimate the incidence of residual blockade in their hospital [selected "don't know"]).
The clinical significance of residual neuromuscular blockade as perceived by respondents is shown in Table 5 . The majority of respondents (63%) believed that "residual neuromuscular blockade represents a significant clinical problem". Anaesthetists reporting a lower estimated incidence of residual neuromuscular blockade frequently reported that it was not a significant clinical problem.
The attitudes of respondents to the use of neuromuscular function monitoring to prevent residual neuromuscular blockade are shown in Table 6 . While 69.3% of respondents felt routine neuromuscular function monitoring would reduce the incidence of residual neuromuscular blockade, they were no more likely to use neuromuscular function monitors than those who perceived a low incidence of residual blockade. However, those who believed residual neuromuscular blockade to be a significant clinical problem were more likely to use neuromuscular function monitoring.
The frequency of use of neuromuscular function monitoring in patients receiving neuromuscular blockade is shown in Table 7 . Only 17% of respondents monitored neuromuscular function often, meaning 83% of respondents used no intraoperative neuromuscular function monitoring or used only subjective confirmation of recovery from neuromuscular blockade.
Availability, types and preferences of neuromuscular transmission monitors
One neuromuscular function monitor of any type per operating room was available in 48.4% of hospitals in which the respondents practised, with Rarely=once a year, sometimes=once a month, frequently=once a week, often=almost daily. 23.3% sharing one monitor between two theatres and 24.6% sharing one between three or more. In 3.5% of the hospitals, no monitors were available.
Factors influencing use of neuromuscular blockade antagonists
Neuromuscular blockade was always antagonised by 37% of respondents. The timing and choice of agents was considered important by 63%. Clinical assessment of reversal, such as tidal volume and grip strength, was used by 47% of respondents and absence of fade using a peripheral nerve stimulator by 25.4%. The adverse side-effects of neostigmine concerned 33.6% of respondents.
Knowledge of current standards for safe neuromuscular blockade antagonism
Only 27% (181) of respondents correctly identified the safe neuromuscular function monitor criteria for extubation and only a similar percentage of 28% (186) correctly identified that subjective assessment of neuromuscular function is unreliable. Fifty percent of respondents relied mostly on clinical judgment.
The opinions of respondents about the usefulness, reliability, availability type and mandating of neuromuscular function monitors are shown in Table 8 .
DISCUSSION
The potential for morbidity and mortality due to neuromuscular-blocking drugs has been known for some time, yet postoperative residual blockade remains common, apparently occurring on a daily basis in most hospitals 4, 5, 18 . Many respondents to our survey felt that there was a relatively low incidence of residual neuromuscular blockade in their patients (Table 4 ). However, this incidence is likely to be an underestimate. There are several potential reasons for underestimating residual neuromuscular blockade: much of this residual block is subclinical; infrequent use of neuromuscular function monitoring may lead to underdiagnosis; and many practitioners have either a low index of suspicion or appear to misunderstand the definitions and diagnostic criteria for residual blockade 6 .
The introduction of the intermediate acting neuromuscular blocking agents vecuronium, cisatracurium and rocuronium may have led to complacency with respondents believing residual blockade is no longer a problem. Anaesthetists may be attributing the effects of residual blockade to other anaesthetic agents or individual patient factors.
Evidence of the inadequacy of clinical tests and subjective neuromuscular function monitoring has been well documented 19 . Despite the majority of respondents (69.3%) believing routine monitoring would reduce the incidence of residual blockade, most patients of respondents (up to 83%) in this survey have no neuromuscular function monitoring or objective confirmation of recovery of neuromuscular function before extubation. Possible reasons for this again include lack of concern for the clinical significance of the problem or a lack of suitable neuromuscular function monitoring equipment. This lack of equipment is surprising given the majority of respondents (79%) believed there should be one neuromuscular function monitor for every operating room and 39% felt these monitors should be quantitative. Capital expenditure required for this equipment is relatively small and the cost of disposables is low. It may also be that respondents felt there is a lack of an appropriate monitor for their practice. Impediments to use of accurate quantitative equipment, such as limited access to a hand able to move without restriction, poor electrode placement and the use of inbuilt algorithms to 'correct' the TOF in some monitors may lead to lack of confidence in some monitors 20 .
Awareness of the research and reviews documenting recent advances in neuromuscular blocking practice appeared to be poor among respondents [5] [6] [7] 21 . This is supported by the findings that over 70% of respondents could not correctly identify the safe criteria for excluding residual neuromuscular blockade before extubation or the limitations of clinical signs and subjective testing. More education in this area is therefore warranted.
When our results are compared with a similar study conducted in Europe and the United States, our respondents seemed to have less awareness of the problem and less belief that monitoring might reduce the problem than their colleagues in the United States or Europe 11 . Over 80% of respondents from Europe and the United States There are many limitations with internet survey research, and in this survey the low response rate may limit its validity due to the possible introduction of bias 22 . The nonresponders could include those without a current email address, or those who are retired or have little interest or knowledge of the subject. Email surveys have been shown to have higher response from younger respondents and those affiliated with an academic institution 14 . Anaesthetists who do not consider residual neuromuscular blockade to be a problem or rarely use neuromuscular blockers may have chosen to ignore the survey as irrelevant to their practice. Being an anonymous and voluntary survey means targeted reminders to nonresponders are not possible. Our response rate of 43% of opened emails in Australia and 25% in New Zealand is significantly better than that of Naguib et al, while the results are largely consistent 11 . Nevertheless, despite the low response rate, the sample size was large and heterogeneous; hence the views of 667 members should not be ignored. The respondents included anaesthetists with a broad range of practice location, duration of experience and size of hospital, so their views are likely to be representative of anaesthetists in Australia and New Zealand more generally. However, in the unlikely scenario that the respondents were not representative, there was still a sufficient number describing attitudes, knowledge and practices that would be of concern.
Another limitation is that we did not differentiate between those using neuromuscular function monitoring to ensure adequate depth of block to facilitate surgery from those who used it to confirm recovery from block. Nevertheless, differentiating those selecting this reason for the use of monitoring could only reduce the numbers of practitioners objectively confirming full recovery from neuromuscular block.
We deliberately did not ask the relevant question, "how often do your patients experience a clinical problem related to incomplete reversal" as we felt that, unless a quantitative assessment of neuromuscular function is made, an accurate diagnosis is not possible. As Donati said, "Faced with a patient who is hypoxemic, has airway obstruction or is not comfortable in the PACU, most anesthesiologists do not spontaneously think of residual neuromuscular blockade as a likely cause" 6 .
This survey identifies a lack of knowledge in the area of neuromuscular blockade equipment and monitoring among anaesthetists in Australia and New Zealand responding to this survey. While the findings apply mostly to the respondents of the survey, it is possible and even likely that they apply more broadly. Provision of more monitors alone will not ensure that residual neuromuscular blockade is eliminated, nor can it ensure the monitors are used correctly or even used at all. There is a need for education and capital investment in this area. Our findings support the strengthening of current guidelines for monitoring of neuromuscular blockade and pose the question, "should objective confirmation of full recovery of neuromuscular function with a quantitative monitor in every patient receiving a neuromuscular blocker be the standard?".
